Alternating magnetic fields enhance anti-biofilm activity across pathogen and antibiotic space Authors: Miranda Hairgrove, Sneha Banerjee, Madhab Sapkota, Gerald Kramer, Varun Sadaphal, Bibin Prasad, Rajiv Chopra, David E Greenberg Published: 2025 ABSTRACT AbstractProsthetic joint infection (PJI) is a severe complication of total joint arthroplasty, contributing to significant patient morbidity and increased healthcare costs. The formation of biofilm on the implant hinders effective therapy, and removal of the prosthesis is frequently required. High frequency alternating magnetic fields (AMF) have emerged as a promising noninvasive approach to disrupt biofilm and have the potential to augment antibiotic activity. This study evaluated the impact of AMF on antibiotic activity in biofilms of clinically relevant PJI pathogens. Across multiple bacterial strains, AMF significantly improved biofilm eradication when administered with antibiotics, achieving greater reductions in bacterial burden compared to antibiotic monotherapy. There was an average reduction of 5.72-log across Gram-positive pathogens when treated with AMF and linezolid, and an average 5.11-log reduction of Gram-negative biofilm when treated with AMF and ciprofloxacin. The bactericidal response was independent of metal composition, suggesting broad applicability to different conductive prosthetic materials. Additionally, biofilm reduction was time and temperature-dependent, with peak efficacy observed at 80 °C. These findings support AMF as a potential adjunctive therapy for PJI, warranting further investigation in clinical settings to optimize treatment strategies and improve patient outcomes.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-31574-1.Keywords: Alternating magnetic fields, Biofilm, Prosthetic joint infectionSubject terms: Diseases, Health care, Medical research, Microbiology Introduction Hip and knee arthroplasties are among the most common orthopedic surgeries performed in the United States, significantly enhancing the quality of life for patients with conditions such as osteoarthritis, autoimmune disorders, and fractures1. However, a serious complication of these procedures is the development of a prosthetic joint infection (PJI), which cannot be cured with antibiotics alone. Although PJI occurs in only 0.6–2% of hip and knee total joint arthroplasties2, they are the leading cause of joint revision surgery3. The current gold standard for PJI treatment is a two-stage revision surgery, in which the infected joint is replaced with a temporary spacer, followed by a prolonged course of antibiotics, and subsequently, a second surgery for definitive joint replacement. Debridement, antibiotics, and implant retention (DAIR) is an alternative approach that involves surgical lavage of the infected joint space and extended antibiotic therapy, but it is not suitable for chronic or drug-resistant infections and is associated with significant recurrence rates4. More recently, emerging strategies such as next-generation antibiotic spacers (e.g., Osteal) and intraosseous antibiotic delivery have been explored to improve infection control. In cases where these treatment options fail, patients may require lifelong antibiotics to suppress infection or amputation5. Even with these treatment strategies, PJIs carry a two-year mortality rate of approximately 7%6 and patients often experience substantial declines in physical, financial, and emotional well-being following revision surgery7. Additionally, a single joint revision surgery can cost between $10,000 and $45,0008, and the financial burden of treating PJIs in the United States is projected to reach $1.85 billion annually by 20309. With over a million hip and knee replacements performed annually—a number expected to rise due to an aging population and increasing rates of diabetes and obesity10—PJIs will continue to present a significant healthcare challenge. Prosthetic implants are composed of a variety of metals, including stainless steel, titanium, and cobalt-chromium-molybdenum alloys19. The persistence and complexity of PJIs stem largely from the formation of biofilm on these metal-surfaces, which consists of extracellular polymeric substances (EPS) that aid microbial adhesion, aggregation, and protection11. Though typically less than 1 mm thick, biofilm creates an effective barrier that shields bacteria from both antibiotics and the host immune response, making eradication particularly challenging11. It has been previously shown that biofilm eradication is time and temperature-dependent, with higher temperatures and longer exposures resulting in larger reductions of biofilm20. As a result, antibiotic therapy alone is insufficient, necessitating surgical intervention as the current standard of care. While various methods, including heat, have been explored for biofilm eradication, most are impractical for prosthetic joints due to challenges with physically accessing the infected prosthetic and the risk of surrounding tissue damage. Prior studies have shown that non-contact induction heating techniques can safely generate localized heat on prosthetic materials without damaging surrounding bone or cement coatings12. High-frequency (> 100 kHz) alternating magnetic fields (AMF) have also emerged as a promising noninvasive alternative13,14. Conductive materials exposed to AMF generate heat on the material surface due to the formation of eddy currents. This heat disrupts the biofilm structure and renders bacteria more susceptible to antibiotics11,14,15. Importantly, AMF can penetrate tissue to reach metal implants while the radius of thermal damage to surrounding structures is minimal12,14,16. Although initial studies have demonstrated the feasibility of AMF for PJI treatment, data has been limited to a narrow range of bacterial strains and antibiotics13,14. Although Gram-positive cocci are identified in most cases of PJI, aerobic Gram-negative bacilli are also known PJI pathogens, particularly in early post-operative infections16. Given that PJIs can be caused by a variety of pathogens, further investigation is needed to determine how broadly active AMF might be. This study aimed to evaluate the effectiveness of AMF across multiple bacterial strains and antibiotic classes to help inform how AMF could be used as an adjunctive therapy for PJI management. Results Across all pathogens and antibiotics tested, there was significant reduction in the biofilm burden in the combination treatment group (AMF + antibiotics) when AMF was delivered as a single 120 s exposure reaching a peak temperature of 80 °C (Figs. 1, 2). We initially focused on the major Gram-positive pathogens responsible for PJI17,18. Across three strains of S. aureus, combination treatment of AMF plus linezolid demonstrated an average 5.49-log CFU/cm2 reduction in biofilm burden compared to no-treatment control (95% CI 4.74–6.24) (Fig. 1). In the same strains, treatment with linezolid alone resulted in an average 0.87-log reduction in biofilm (95% CI 0.13–1.62). Similar decreases were seen with combination therapy with AMF plus minocycline (6.03-log reduction, 95% CI 5.28–6.78) versus minocycline alone (2.66-log, 95% CI 1.91–3.40). Treatment with trimethoprim-sulfamethoxazole (TMP-SMX) behaved similarly to the other antibiotics demonstrating significant reductions when combined with AMF (5.98-log, 95% CI 5.23–6.72) compared to TMP-SMX monotherapy (2.41-log, 95% CI 1.66–3.16). The response to combination therapy was independent of the Staphylococcus species or resistance phenotype, as strains of S. epidermidis behaved similarly. Other Gram-positive pathogens that can cause PJI were assessed for AMF responsiveness. In Enterococcus faecalis, combination therapy reduced biofilm when treated with linezolid by 6.09-log (95% CI 5.28–6.91) or ampicillin 5.02-log (95% CI 3.42–6.62) in two different strains, compared to linezolid or ampicillin monotherapy which reduced biofilm by 0.87-log (95% CI 0.40–1.33) and 3.96-log (95% CI 2.23–5.69), respectively (Fig. 1). AMF works synergistically with antibiotics to eradicate metal-associated biofilm in select Gram-positive bacteria. Biofilm was grown on stainless-steel rings for 48 h with various strains of Staphylococcus aureus (A), S. epidermidis (B), and Enterococcus faecalis (C). Each colored circle represents individual strains as indicated in the legends. S. aureus and S. epidermidis antibiotic exposures: linezolid (LZD, 2 µg/mL), minocycline (MIN, 0.5 µg/mL), and trimethoprim-sulfamethoxazole (TMP-SMX, 4 µg/mL). E. faecalis antibiotic exposures: ampicillin (AMP, 2 µg/mL) and linezolid (LZD, 2 µg/mL for strain 7667, 4 µg/mL for strain 7676). Colony-forming units were counted 24 h post-AMF treatment and reported as log (CFU/cm2) on the stainless-steel rings. Error bars indicate mean with SD. CFU limit of detection (LOD) = 0.78 log (CFU/cm2). One-way ANOVA. Statistical significance: p < 0.0001 (*). AMF works synergistically with antibiotics to eradicate biofilm caused by Gram-negative biofilms. Biofilm was grown on stainless-steel rings for 48 h with various strains of Pseudomonas aeruginosa (A) and Escherichia coli (B). Each colored circle represents individual strains as indicated in the legends. P. aeruginosa antibiotic exposures: ceftazidime-avibactam (CAZ-AVI, 4 µg/mL), ciprofloxacin (CIP, 0.5 µg/mL for strains PAO1 and PA103, 4 µg/mL for 4847). E. coli antibiotic exposures: ciprofloxacin (CIP, 0.1 µg/mL) and ceftriaxone (CTX, 0.1 µg/mL). Colony-forming units were counted 24 h post-treatment and reported as log (CFU/cm2) on the stainless-steel rings. Error bars indicate mean with SD. CFU limit of detection (LOD) = 0.78 log (CFU/cm2). One-way ANOVA. Statistical significance: p < 0.0001 (*). Significant reductions in Pseudomonas aeruginosa and Escherichia coli biofilm were seen when treated with AMF plus ceftazidime-avibactam (CAZ-AVI), ciprofloxacin, and ceftriaxone (Fig. 2). In P. aeruginosa, AMF plus CAZ-AVI reduced biofilm by an average of 4.392-log (95% CI 2.17–6.61), while CAZ-AVI monotherapy reduced biofilm burden by 2.68-log (95% CI -0.15–4.29) compared to that of no-treatment controls. P. aeruginosa treated with AMF and ciprofloxacin resulted in a 5.98-log reduction (95% CI 3.76–8.20), while ciprofloxacin monotherapy showed a decrease of 2.68-log (95% CI 0.46–4.90). E. coli demonstrated a 5.20-log reduction in biofilm when treated with AMF plus ciprofloxacin (95% CI 4.67–5.73), and a 5.12-log reduction with AMF plus ceftriaxone (95% CI 4.79–5.45). Antibiotic monotherapy with ciprofloxacin or ceftriaxone in E. coli resulted in 0.61-log (95% CI 0.14–1.07) and 1.93-log (95% CI 1.50–2.37) reductions, respectively. Across all tested organisms, combination therapy with antibiotics plus AMF was significantly more effective at reducing biofilm on metal rings than antibiotics-alone (p < 0.0001). To assess if metal composition impacted AMF responsiveness, we compared both biofilm formation and eradication on steel and titanium rings. S. aureus, S. epidermidis, and P. aeruginosa all displayed similar levels of biofilm growth on both stainless steel and titanium rings when compared across the same species (p > 0.05). Additionally, all species demonstrated a similar reduction of biofilm when exposed to AMF plus antibiotics regardless of metal composition (p > 0.1) (Fig. 3). Biofilm growth and response to AMF is consistent on both stainless-steel and titanium surfaces. Similar levels of biofilm develop on rings grown on stainless-steel (SS) or titanium (Ti) rings across S. aureus (strain 4136), S. epidermidis (strain 7161), and P. aeruginosa (PAO1) (A). Additionally, there is no significant difference in the reduction of P. aeruginosa biofilm in response to AMF plus antibiotics between stainless-steel and titanium rings (B). Antibiotic exposure: ceftazidime/avibactam (CAZ-AVI, 4 µg/mL), ciprofloxacin (CIP, 0.5 µg/mL). AMF delivered with a peak temperature of 80 °C over a single 120 s exposure. Colony-forming units were counted 24 h post-treatment and reported as log (CFU/cm2) on the stainless-steel rings. Error bars indicate mean with SD. CFU limit of detection (LOD) = 0.78 log (CFU/cm2). One-way ANOVA. Statistical significance: p > 0.1 (ns). We next explored the impact of both temperature and AMF exposure time in conjunction with antibiotics. In MRSA 1675 strain, reduction of biofilm when combined with antibiotics showed a temperature-dependent response (Fig. 4). A peak temperature of 80 °C was most effective at eradicating 1675 MRSA biofilm compared to 75 °C, 65 °C, and 55 °C. Combination treatment of AMF (peak temperature of 80 °C) plus linezolid reduced biofilm by 5.52-log after 24 h. Combination treatment of AMF reaching peak temperatures of 75 °C, 65 °C, and 55 °C resulted in 2.95-log, 2.94-log, and 1.66-log reductions, respectively. AMF activity is dependent on duration and temperature. S. aureus strain 1675 (A) MRSA with 1 µg/mL linezolid was tested across various AMF peak temperatures. Combination therapy of linezolid plus AMF reaching peak temperatures of 65 °C, 75 °C, and 80 °C were significantly more effective at reducing biofilm burden than a peak temperature of 55° C (p < 0.05) (B) P. aeruginosa treated with cipro or ceftazidime-avibactam with AMF delivered as 1-single exposure (120 s) versus 3 40-s exposures reaching a peak temperature of 80 °C. Colony-forming units were counted 24 h post-treatment and reported as log (CFU/cm2) on the stainless-steel rings. Error bars indicate mean with SD. CFU limit of detection (LOD) = 0.78 log (CFU/cm2). One-way ANOVA. Statistical significance: p > 0.05 (ns), < 0.033 (*), 0.002 (**), < 0.001 (***). In Pseudomonas aeruginosa, when in combination with either CAZ-AVI or ciprofloxacin, a single 120-s exposure reaching a peak temperature of 80 °C was superior at reducing Pseudomonas aeruginosa biofilm compared to three exposures reaching a peak temperature of 80 °C and lasting 40 s each with the same antibiotics. Materials and methods Bacterial strains and growth conditions We included the following PJI-associated pathogens for investigation: methicillin-sensitive and resistant clinical strains of Staphylococcus aureus and Staphylococcus epidermidis, Enterococcus faecalis, Pseudomonas aeruginosa, and Escherichia coli (Supplemental Table 1)18. Bacterial strains were laboratory strains or clinical isolates collected from the William P. Clements Jr. University Hospital and part of the Texas Infectious Diseases Biorepository (TIDB) (Supplemental Table 1) (IRB-approved study protocol # STU-2018–0319). Strain numbers designate identifiers of the isolates in the TIDB biorepository. Frozen bacterial stocks were maintained at − 80 °C in glycerol and revived on blood agar plates before inoculation into liquid media. Antibiotic selection and MIC determination The antibiotics used were linezolid, minocycline, trimethoprim-sulfamethoxazole (TMP-SMX), ciprofloxacin, and ceftazidime-avibactam (CAZ-AVI). All antibiotics were obtained from the William P. Clements Jr. University Hospital pharmacy. Decisions on antibiotics and dosages for each strain were made based on their minimum inhibitory concentration (MIC) data (Supplemental Table 1). Biofilms were treated with 4 × MIC values for any given strain, independent of the antibiotic used. MIC values were determined using broth microdilution assays and defined as the lowest antimicrobial concentration that inhibited visible bacterial growth after 24 h of incubation. Biofilm formation Isolated colonies were obtained from streak plates of the desired strain and inoculated into 2 mL of media to create a starting culture. The media used was tryptic soy broth (TSB, BD 211,825) for Staphylococcus species, TSB supplemented with 1% sucrose (TSB 1% sucrose) for Enterococcus species, Mueller Hinton II (MHII, BD 212,322) media for Pseudomonas species, and lysogeny broth (LB, BD 244,620) for Enterococcus coli. The starting culture was transferred to a shaking incubator for 4 h at 37 °C and 220 RPM, with the exclusion of Enterococcus which was maintained under stationary conditions. The culture was then diluted in Dulbecco’s phosphate-buffered saline (DPBS) to an OD600 of 0.075, measured using a Genesys 50 spectrophotometer (ThermoFisher). This OD600 corresponds to approximately 1 × 108 CFU/mL, as determined from a standard curve generated by plating serial dilutions of the culture and enumerating colonies. The culture was subsequently diluted 1:200 in DPBS to obtain a working inoculum of ~ 5 × 105 CFU/mL. Media (TSB for Staphylococcus spp., TSB 1% sucrose for E. faecalis, MHII for P. aeruginosa, LB for E. coli) was inoculated with the starting culture to obtain a working solution with a bacterial concentration of 5 × 105 CFU/mL. Biofilms were grown by placing stainless-steel or titanium rings in media as previously described14 with 5 mL of working solution in 50 mL conical tubes and incubating at 37 °C and 110 RPM for 42–45 h, except for Enterococcus which remained stationary. The stainless-steel ring had dimensions of 19.05 mm in diameter, 0.89 mm in thickness, and 5.08 mm in length, while the titanium ring had dimensions of 19.05 mm in diameter, 0.89 mm in thickness, and 6.35 mm in length. Media were decanted and replenished at 24 h during incubation. AMF device Alternating magnetic field (AMF) exposure was carried out using a custom-built system consisting of a single solenoid coil. Inside the coil, two stacked racks each containing eight slots (total capacity: sixteen 50 mL centrifuge tubes) were used to biofilm-coated metal rings. The system is operated through a laptop-controlled setup: function generator → RF amplifier → power meter → matching circuit → solenoid coil, with samples positioned inside the coil for uniform exposure. The AMF system was calibrated to achieve the desired peak temperature by adjusting the magnetic field strength at the coil center, while maintaining a fixed frequency of 214.5 kHz (Supplementary Table 5). Calibration was performed using fiber-optic temperature sensors placed on the inner surface of metal rings to determine the frequency, amplitude, and exposure time required to reach specific temperature targets. During experiments, these pre-calibrated parameters were applied directly to the AMF device. Treatment Treatment conditions included: no-treatment controls (no AMF, no antibiotic), AMF only, antibiotic only, and AMF plus antibiotic. After 48 h of biofilm growth, the rings were transferred to fresh media (10 mL of TSB, TSB 1% sucrose, MHII, or LB, based on the tested strain) that was pre-heated to 37 °C. The antibiotic-treatment groups (antibiotic-only and AMF-plus-antibiotic groups) received antibiotic doses equal to 4 times the minimum inhibitory concentration (MIC) determined for each pathogen. Prior to AMF treatment, tubes designated for AMF exposure were equilibrated in a 37 °C incubator for 30 min. AMF treatment groups were then subjected to different exposure parameters, such as longer or shorter durations to reach different average temperatures (55, 65, 75, or 80 °C) or having the AMF delivered as a single or multiple exposures. The standard delivery of AMF was a single 120 s exposure reaching a peak temperature of 80 °C, unless stated otherwise. After treatment with AMF, the rings were transferred to fresh media with or without antibiotics to minimize non-adherent bacteria. All treatment groups were then incubated without shaking at 37 °C until harvest. Sample harvesting & bacterial quantification Samples were harvested at 1 and 24-h post-treatment. Harvested rings were rinsed in 5 mL DPBS to minimize non-adherent bacteria in all treatment groups. Samples were transferred to 4 mL DPBS tubes and sonicated in an ultrasonic water bath (Vevor Digital Ultrasonic Cleaner) at room temperature for 5 min at a frequency of 40 kHz and a power output of 120 W. Samples were serially diluted and plated on blood agar. Agar plates were incubated at 37 °C for 24 h for a viable cell count. Statistical analysis Colony counts and dilution factors were used to calculate the total bacterial burden per surface area (CFU/cm2) on the rings, and the formula used to calculate log (CFU/cm2) can be expressed as: Log-transformed values were then analyzed across treatment conditions. Each condition included 4 replicates (2 biological replicates, each with 2 technical replicates). Statistical analyses were performed using GraphPad Prism (version 10; GraphPad Software, San Diego, CA). Treatment groups at 24 h were compared to the 24-h no-treatment control using one-way ANOVA. When ANOVA indicated significant differences, Tukey’s multiple-comparison post-hoc test was applied. P-values are reported in accordance with the NEJM style output in GraphPad (e.g., p < 0.033, p < 0.002, p < 0.001), which reflect adjusted thresholds following multiple comparisons correction. Discussion The study’s findings demonstrate that the combination of high frequency alternating magnetic fields (AMF) and antibiotics significantly enhanced biofilm eradication in a variety of clinically relevant PJI pathogens. Importantly, this effect was consistent across different metal compositions, supporting the broad applicability of AMF for treatment of prosthetic joint infections. Although we showed a temperature-dependent effect of AMF and antibiotics in a single strain of S. aureus, previous publications have demonstrated similar patterns with other pathogens and antibiotics both in vitro and in vivo14,24. Notably, a single 120-s AMF exposure reaching 80 °C was more effective than three 40-s exposures reaching the same peak temperature, suggesting that length of exposure is one factor that plays a role in disrupting biofilm structure. Biofilm remains one of the most challenging complications in orthopedic surgery, with significant morbidity, mortality, and associated healthcare costs. Current treatment strategies, including two-stage revision surgery and DAIR, are invasive and associated with prolonged recovery times6–8. Despite these interventions, the recurrence of infection remains a risk, particularly in chronic cases or infections caused by multidrug-resistant organisms4. Our findings suggest that AMF could serve as a valuable adjunctive therapy, improving the efficacy of antibiotic treatment and potentially reducing the need for multiple revision surgeries. In recent years, DAIR has gained attention as a less invasive alternative to two-stage revision surgery. However, DAIR alone has demonstrated variable success rates, and is not recommended for chronic infections4. Since AMF has shown efficacy against methicillin-resistant Staphylococci and other PJI-associated pathogens, integrating AMF into DAIR protocols may enhance bacterial eradication and improve long-term outcomes. By reducing the bacterial load and disrupting biofilms, AMF may help lower recurrence rates and extend the viability of DAIR as a treatment option, particularly for patients who are otherwise poor candidates for more intensive surgery such as two-stage revision. In our recent sheep safety study, AMF exposure of implanted metal hardware achieved biofilm reduction without inducing adjacent muscle necrosis, thermal injury, or impaired wound healing16. Histopathological analysis confirmed preservation of peri-implant soft tissue architecture, indicating that the localized heating produced by AMF is well tolerated in vivo. These in vivo findings validated previous studies demonstrating that by utilizing the skin effect, we can limit heat transfer to small areas of tissue that are directly in contact with an implant25,26. Although 80 °C was the temperature that was chosen for many of the experiments in this study, we have found lower temperatures are efficacious as well, both in vitro and in vivo. Future clinical trials will assess the safety and efficacy of AMF initially as a DAIR adjunct at the time of surgery using treatment times that are compatible with use in an operating room setting. Feasibility studies assessing the safety of low-temperature AMF treatment utilizing a clinical ready device in human patients have now completed enrollment and pivotal trials are anticipated to start in the near future. The mechanism underlying AMF’s efficacy in biofilm eradication is likely multifactorial. Biofilms protect bacteria through an extracellular polymeric substance (EPS) matrix, which serves as a physical and chemical barrier to antibiotics and immune cells11. AMF-induced heating likely disrupts this matrix, increasing bacterial susceptibility to antibiotics. Additionally, thermal stress can directly damage bacterial membranes and proteins, leading to cell death as well as overcoming certain mechanisms of antibiotic resistance20. The improved outcomes observed with a continuous 120-s exposure versus multiple shorter exposures remain to be fully understood. A likely explanation is that with shorter exposures, higher temperatures (> 50 °C) are applied to the implant for a brief period, whereas continuous, longer exposures subject the implant to elevated temperatures for an extended duration, resulting in a significantly greater thermal effect compared to multiple short exposures. Additionally, for clinical implants, prolonged exposure helps achieve a more uniform temperature distribution. This suggests that prolonged exposure enhances the depth and extent of biofilm disruption, maximizing bactericidal effects. Our results demonstrate that AMF works equally well across different metal compositions. Given that most orthopedic implants are composed of titanium, stainless steel, or cobalt-chromium alloys, AMF therapy can be readily adapted to a wide range of prosthetic devices with minor coil calibration adjustments. Importantly, a critical feature of coil design is the ability to generate magnetic fields that heat a complex shape, such as a knee, within a tight temperature range. Our use of simulation followed by biological validation of coils has allowed us to create a small number of coils that can evenly heat a broad range of implants for a given anatomic site. Additionally, since polyethylene tibial inserts are non-conductive and would not generate heat in response to AMF, their presence in knee replacements should not interfere with treatment, though AMF will likely not be sufficient to address biofilm on the insert itself. Future clinical trials will assess the impact of leaving the spacer in place when deploying AMF as a surgery sparing treatment modality. The increasing prevalence of antibiotic resistance presents a major challenge in PJI management21. Biofilms not only protect bacteria from host immune responses but also can facilitate the exchange of genetic material, promoting the development of antibiotic resistance22. By physically disrupting biofilms, AMF may enhance antibiotic penetration and activity, potentially rescuing antibiotic efficacy against resistant strains depending on the mechanism of resistance that is present. In addition, AMF-induced thermal stress may directly compromise bacterial cell walls, membranes, and intracellular components, rendering bacteria more susceptible to antimicrobial agents. Prior work suggests that AMF may be able to rescue pathogens from membrane-mediated resistance mechanisms due to thermal membrane destruction14. Further studies are needed to determine all the mechanisms that drive this synergistic response between antibiotics and AMF. While our findings provide strong support for AMF as an adjunctive therapy in PJI treatment, an area for further investigation is the efficacy of AMF against atypical PJI pathogens, such as non-tuberculous mycobacteria and fungal infections. These infections, though less common, often occur in immunocompromised patients and pose significant treatment challenges due to their intrinsic resistance to conventional antibiotic therapies23. Other limitations include the lack of testing a wide range of surface induced temperatures. Although we have demonstrated a temperature and time-dependent effect of AMF on biofilm reduction, we have not explored the implications of repeated exposure of AMF across a large number of pathogens to ensure that AMF retains activity after multiple doses. Our testing of more than one strain for each of the test pathogens gives us initial reassurance that we will have broad activity across different strains for any given species. This study demonstrates that a single exposure of AMF, when used with antibiotics, significantly enhances biofilm eradication across multiple PJI pathogens, independent of metal composition. The time and temperature dependent nature of AMF-induced bacterial disruption highlights the importance of optimizing treatment parameters for future clinical applications. Given the high burden of PJI on patients and healthcare systems, AMF represents a promising noninvasive adjunctive therapy with the potential to improve treatment efficacy, reduce recurrence rates, and mitigate antibiotic resistance. Future research should focus on clinical translation and expanding the scope of AMF to include atypical and polymicrobial infections. Supplementary Information Supplementary Information. Acknowledgements Special thanks to Christine Pybus and Leona White for their assistance with aspects of this project. Dr. Greenberg is the inventor of the AMF technology and is the Chief Medical Officer of Solenic Medical. Author contributions D.E.G. assisted with experimental design and data interpretation. M.H. and S.B. contributed equally to data acquisition, analysis, and manuscript writing, and are recognized as co–first authors. M.S. and G.K. assisted with complementary in vitro data collection and manuscript editing. V.S. constructed the AMF coil used in the experiments, and B.P. conducted system simulations and temperature validation. R.C. and D.E.G. are inventors of the AMF device and provided overall resources, funding, and project supervision. Funding This work was sponsored by a research agreement from Solenic Medical (PI DG) and in part from NIAID R44AI155291 (co-PI Greenberg). Data availability The data comprise bacterial burden for Gram-positive and Gram-negative strains of bacteria (Supplemental Table 1). Some isolates were obtained through the Texas Infectious Diseases Biorepository (TIDB) under IRB-approved study protocol # STU-2018–0319. Declarations Competing interests D.E.G. and R.C. are inventors of the AMF device and are employees and/or consultants for Solenic Medical. D.E.G. and R.C. own stock in Solenic Medical. B.P. and V.S. are employees of Solenic Medical. Remaining authors do not have any competing interests to declare. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Miranda Hairgrove and Sneha Banerjee contributed equally to this work and are listed as co-first authors. Author order reflects relative seniority. References Associated Data Supplementary Materials Supplementary Information. Data Availability Statement The data comprise bacterial burden for Gram-positive and Gram-negative strains of bacteria (Supplemental Table 1). Some isolates were obtained through the Texas Infectious Diseases Biorepository (TIDB) under IRB-approved study protocol # STU-2018–0319.